Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China

References

• World Health Organization. Global tuberculosis report. 2018 Available from: http://www.who.int/tb/publications/global_report/en;2018. Accessed 78, 2019.
   Google Scholar
• Stehr M, Elamin AA, Singh M. Pyrazinamide: the importance of uncovering the mechanisms of action in mycobacteria. Expert Rev Anti Infect Ther. 2015;13:593–603. doi:10.1586/14787210.2015.102178425746054
   PubMed Web of Science ®Google Scholar
• Ramirez-Busby SM, Valafar F. Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother. 2015;59:5267–5277. doi:10.1128/AAC.00204-1526077261
   PubMed Web of Science ®Google Scholar
• Streicher EM, Maharaj K, York T, et al. Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibility. J Clin Microbiol. 2014;52:4056–4057. doi:10.1128/JCM.02438-1425165081
   PubMed Web of Science ®Google Scholar
• World Health Organization. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. 2018 Available from: http://apps.who.int/medicinedocs/documents/s23565en/s23565en.pdf. Accessed 78, 2019.
   Google Scholar
• Yadon AN, Maharaj K, Adamson JH, et al. A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide. Nat Commun. 2017;8:588. doi:10.1038/s41467-017-00721-228928454
   PubMed Web of Science ®Google Scholar
• Zignol M, Dean AS, Alikhanova N, et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis. 2016;16:1185–1192. doi:10.1016/S1473-3099(16)30190-627397590
   PubMed Web of Science ®Google Scholar
• Khan MT, Malik SI, Ali S, et al. Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan. BMC Infect Dis. 2019;19:116. doi:10.1186/s12879-019-3764-230728001
   PubMed Web of Science ®Google Scholar
• Daneau G, Gumusboga M, De Rijk P, et al. The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide. Int J Mycobacteriol. 2016;(Suppl 1):S46–S47. doi:10.1016/j.ijmyco.2016.10.01528043604
   PubMedGoogle Scholar
• Ngabonziza JCS, Diallo AB, Tagliani E, et al. Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide. PLoS One. 2017;12:e0187211. doi:10.1371/journal.pone.018721129088294
   PubMed Web of Science ®Google Scholar
• Sengstake S, Bergval IL, Schuitema AR, et al. Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia. BMC Infect Dis. 2017;17:491. doi:10.1186/s12879-017-2594-328697808
   PubMed Web of Science ®Google Scholar
• Li D, Song Y, Zhang CL, Li X, Xia X, Zhang AM. Screening mutations in drug-resistant Mycobacterium tuberculosis strains in Yunnan, China. J Infect Public Health. 2017;10:630–636. doi:10.1016/j.jiph.2017.04.00828623123
   PubMed Web of Science ®Google Scholar
• World Health Organization. Laboratory Services in Tuberculosis Control. Part III: Culture. Geneva: World Health Organization; 1998 Available from: http://apps.who.int/iris/bitstream/handle/10665/65942/WHO_TB_98.258_(part3).pdf;jsessionid=64EF54513AD4144A520B24B4E3DFCBA5?sequence=3. Accessed 78, 2019.
   Google Scholar
• Miotto P, Cabibbe AM, Feuerriegel S, et al. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. MBio. 2014;5:e01819–14. doi:10.1128/mBio.01819-1425336456
   PubMed Web of Science ®Google Scholar
• Lan Y, Li Y, Chen L, Zhang J, Zhang H. Drug resistance profiles and trends in drug-resistant tuberculosis at a major hospital in Guizhou Province of China. Infect Drug Resist. 2019;12:211–219. doi:10.2147/IDR.S18853830666136
   PubMed Web of Science ®Google Scholar
• Zignol M, Dara M, Dean AS, et al. Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data. Drug Resist Updat. 2013;16:108–115. doi:10.1016/j.drup.2014.02.00324631052
   PubMed Web of Science ®Google Scholar
• Pang Y, Zhu D, Zheng H, et al. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. BMC Infect Dis. 2017;17:711. doi:10.1186/s12879-017-2761-629110640
   PubMed Web of Science ®Google Scholar
• Xia Q, Zhao LL, Li F, et al. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Zhejiang, China. Antimicrob Agents Chemother. 2015;59:1690–1695. doi:10.1128/AAC.04541-1425583712
   PubMed Web of Science ®Google Scholar
• Bhuju S, Fonseca Lde S, Marsico AG, et al. Mycobacterium tuberculosis isolates from Rio de Janeiro reveal unusually low correlationbetween pyrazinamide resistance and mutations in the pncA gene. Infect Genet Evol. 2013;19:1–6. doi:10.1016/j.meegid.2013.06.00823770140
   PubMed Web of Science ®Google Scholar
• Alexander DC, Ma JH, Guthrie JL, Blair J, Chedore P, Jamieson FB. Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA. J Clin Microbiol. 2012;50:3726–3728. doi:10.1128/JCM.00620-1222895038
   PubMed Web of Science ®Google Scholar
• Cuevas-Córdoba B, Xochihua-González SO, Cuellar A, Fuentes-Dominguez J, Zenteno-Cuevas R. Characterization of pncA gene mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from Mexico. Infect Genet Evol. 2013;19:330–334. doi:10.1016/j.meegid.2012.12.01323321280
   PubMed Web of Science ®Google Scholar
• Sheen P, Requena D, Gushiken E, et al. A multiple genome analysis of Mycobacterium tuberculosis reveals specific novel genes and mutations associated with pyrazinamide resistance. BMC Genomics. 2017;18:769. doi:10.1186/s12864-017-4146-z29020922
   PubMed Web of Science ®Google Scholar
• Kahbazi M, Sarmadian H, Ahmadi A, et al. Novel mutations in pncA gene of pyrazinamide resistant clinical isolates of Mycobacterium tuberculosis. Sci Pharm. 2018;86:pii:15. doi:10.3390/scipharm86020015
   Web of Science ®Google Scholar
• Andres S, Gröschel MI, Hillemann D, Merker M, Niemann S, Kranzer K. A diagnostic algorithm to investigate pyrazinamide and ethambutol resistance in rifampin-resistant Mycobacterium tuberculosis isolates in a low-incidence setting. Antimicrob Agents Chemother. 2019;63:e01798–18. doi:10.1128/AAC.01798-1830455227
   PubMed Web of Science ®Google Scholar
• Akhmetova A, Kozhamkulov U, Bismilda V, et al. Mutations in the pncA and rpsA genes among 77 Mycobacterium tuberculosis isolates in Kazakhstan. Int J Tuberc Lung Dis. 2015;19:179–184. doi:10.5588/ijtld.14.030525574916
   PubMed Web of Science ®Google Scholar
• Marttila HJ, Marjamäki M, Vyshnevskaya E, et al. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia. Antimicrob Agents Chemother. 1999;43:1764–1766.10390239
   PubMed Web of Science ®Google Scholar
• Juréen P, Werngren J, Toro JC, Hoffner S. Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2008;52:1852–1854. doi:10.1128/AAC.00110-0818316515
   PubMed Web of Science ®Google Scholar
• Yüksel P, Tansel O. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Turkey. New Microbiol. 2009;32:153–158.19579692
   PubMed Web of Science ®Google Scholar
• Daum LT, Konstantynovska OS, Solodiankin OS, et al. Characterization of novel Mycobacterium tuberculosis pncA gene mutations in clinical isolates from the Ukraine. Diagn Microbiol Infect Dis. 2019;93:334–338. doi:10.1016/j.diagmicrobio.2018.10.01830583880
   PubMed Web of Science ®Google Scholar
• Muthaiah M, Jagadeesan S, Ayalusamy N, et al. Molecular epidemiological study of pyrazinamide-resistance in clinical isolates of Mycobacterium tuberculosis from South India. Int J Mol Sci. 2010;11:2670–2680. doi:10.3390/ijms1107267020717529
   PubMed Web of Science ®Google Scholar
• Chaidir L, Ruesen C, Dutilh BE, et al. Use of whole-genome sequencing to predict Mycobacterium tuberculosis drug resistance in Indonesia. J Glob Antimicrob Resist. 2019;16:170–177. doi:10.1016/j.jgar.2018.08.01830172045
   PubMed Web of Science ®Google Scholar
• Aung WW, Ei PW, Nyunt WW, et al. Pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Myanmar. Antimicrob Agents Chemother. 2018;62:e01984–17. doi:10.1128/AAC.01984-1729263056
   PubMed Web of Science ®Google Scholar
• Jonmalung J, Prammananan T, Leechawengwongs M, Chaiprasert A. Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. BMC Microbiol. 2010;10:223. doi:10.1186/1471-2180-10-22320727143
   PubMed Web of Science ®Google Scholar
• Gu Y, Yu X, Jiang G, et al. Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a nationalreferral center of China and its correlations with pncA, rpsA, and panD gene mutations. Diagn Microbiol Infect Dis. 2016;84:207–211. doi:10.1016/j.diagmicrobio.2015.10.01726775806
   PubMed Web of Science ®Google Scholar
• Li D, Hu Y, Werngren J, et al. Multicenter study of the emergence and genetic characteristics of pyrazinamide-resistant tuberculosis in China. Antimicrob Agents Chemother. 2016;60:5159–5166. doi:10.1128/AAC.02687-1527297481
   PubMed Web of Science ®Google Scholar
• Cui Z, Wang J, Lu J, Huang X, Zheng R, Hu Z. Evaluation of methods for testing the susceptibility of clinical Mycobacterium tuberculosis isolates to pyrazinamide. J Clin Microbiol. 2013;51:1374–1380. doi:10.1128/JCM.03197-1223390285
   PubMed Web of Science ®Google Scholar
• Ando H, Mitarai S, Kondo Y, et al. Pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis isolates in Japan. Clin Microbiol Infect. 2010;16:1164–1168. doi:10.1111/j.1469-0691.2009.03078.x19832709
   PubMed Web of Science ®Google Scholar
• Jnawali HN, Hwang SC, Park YK, et al. Characterization of mutations in multi- and extensive drug resistance among strains of Mycobacterium tuberculosis clinical isolates in Republic of Korea. Diagn Microbiol Infect Dis. 2013;76:187–196. doi:10.1016/j.diagmicrobio.2013.02.03523561273
   PubMed Web of Science ®Google Scholar
• Huy NQ, Lucie C, Hoa TTT, et al. Molecular analysis of pyrazinamide resistance in Mycobacterium tuberculosis in Vietnam highlights the high rate of pyrazinamide resistance-associated mutations in clinical isolates. Emerg Microbes Infect. 2017;6:e86. doi:10.1038/emi.2017.7329018250
   PubMed Web of Science ®Google Scholar
• CRyPTIC Consortium and the 100,000 Genomes Project, et al. Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing. N Engl J Med. 2018;379:1403–1415. doi:10.1056/NEJMoa180047430280646
   PubMed Web of Science ®Google Scholar